TransMedics Group, Inc.

We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the Organ Care System (OCS) to replace a decades-old standard of care. Our OCS technology replicates many aspects of the organ's natural living and functioning environment outside of the human body, transforming organ preservation for transplantation from a static state to a dynamic environment that enables organ optimization and assessment. We also developed our National Organ Procurement (NOP), a turnkey solution providing outsourced organ procurement, OCS perfusion management, and transplant logistics services, including aviation transportation, ground transportation, and other coordination activity, to transplant programs in the United States. We designed the OCS as a platform to leverage core technologies across products for multiple organs. To date, we have developed three OCS products: OCS Heart, OCS Lung, and OCS Liver. The OCS is the only FDA approved, portable, multi-organ, warm perfusion technology platform. All three products have received Pre-Market Approval (PMA) from the FDA for both organs donated after brain death (DBD organs) and organs donated after circulatory death (DCD organs). Organ transplantation is the treatment for end-stage organ failure, but transplant volumes have been restricted by the limitations of cold storage, the standard of care for solid organ transplantation.